<DOC>
	<DOCNO>NCT01540812</DOCNO>
	<brief_summary>Trial protocol intend optimization induction treatment : 1 . Inclusion PEG-ASP induction three block consolidation . 2 . Reduction dose daunorubicin , recent study show use high dos anthracyclines bring high response rate longer duration 3 . Replacing poor cytological response day 14 level ER end induction criterion decide treatment ( consolidation second induction ) , one criterion ( ER ) throughout study decision making . For another hand , reduce non-essential drug consolidation block try reduce toxicity , replace ASP E. coli induction consolidation PEG-ASP ensure sustain asparagine depletion . Also , increase dose methotrexate ( 3 5 g/m2 ) patient ALL-T , since recent evidence high response rate strategy . Performing allo-HSCT early ( one cycle consolidation ) patient inadequate level ER two cycle induction patient require two course induction obtain proper ER second . Conducting study RD centrally cytofluorometry follow Euroflow consensus standard , avoid bias make treatment decision</brief_summary>
	<brief_title>Treatment Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>ALL de novo highrisk criterion Age 1555 year ( 5560 year patient include discretion medical team attend ) No prior treatment , except Emergency leukapheresis Emergency treatment hyperleukocytosis hydroxyurea Urgent cranial irradiation ( one dose ) CNS leukostasis Mediastinal irradiation urgent superior vena cava syndrome General condition suitable scale ( ECOG 02 ) , &gt; 2 due ALL Negative pregnancy test woman childbearing age Written inform consent , although protocol include use investigational drug , biological sample send L3 type ALL mature phenotype B ( sIg + ) cytogenetic abnormality characteristic mature BALL ( ( 8 ; 14 ) , ( 2 , 8 ) , ( 8 ; 22 ) ) . For patient available BURKIMAB protocol . LAL Ph ( BCRABL ) positive . For patient protocol ALLPh08 ( 55 ) LALOPh ( 55 ) . Lymphoid blast crisis chronic myeloid leukemia Biphenotypic acute leukemia bilinear accord criterion EGIL group Undifferentiated acute leukemias Patients history coronary artery disease , valvular hypertensive heart disease , contraindicate use anthracyclines Patients chronic phase activity Patients severe chronic respiratory failure Kidney failure due ALL Serious neurological disorder due LAL History pancreatitis Pregnancy breastfeed Mental psychiatric illness prevent informed consent give send sample properly follow study General condition affect , attributable ALL</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
</DOC>